Dr. DEVOS MD
ActiveSummary
Dr. DEVOS MD has been active since 2009 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€42,497) and a net result of -€4,762. Equity has been stable since 2018 (±1.6% per year). Its solvency ranks better than 5% of 783 sector peers (NACE 86, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 21-08-2009 Normal situation
- Activity
- Specialist medical practice NACE 86220
- Establishment units
- 2.180.787.553 1210 Sint-Joost-ten-Node, since 09-09-2009
- 2.180.787.751 7880 Flobecq, since 09-09-2009
- Financial year end
- 31 December
- Peppol
- Reachable since 31-12-2025
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.3%
Annual accounts 2025
- Gross margin
- -€4,543
- Loss
- €4,762
- Equity
- -€42,497
- ▼ 12.6%
- Total assets
- €2,737
- ▼ 34.6%
- Negative equity on 31-12-2025
- 2025 accounts filed 28 days after the deadline
Score breakdownraises riskCapped at 59: negative equityLoss of €4,762 (financial year 2025)Negative equity -€42,497lowers riskSize: total assets €2,737Sector: Human health activities (NACE 86)Show the evidence
Checked score
Score 2025
53
/ 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 12% of micro companies in human health (NACE 86)
Negative equity caps the score at 59. Every signal that counts is listed under Signals.
Financial strength · tick: 2024
Weak
Solvency
0=
equity -1552.9% of total assets
Liquidity
50=
short-term debt 291.9% · cash 100.0%
Profitability
0-100
return on assets -174.0%
Bankruptcy probability within 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025lowest value
03-2025: 0.2%▲ +0.1 percentage points vs 02-2025
04-2025: 0.2%● unchanged vs 03-2025
05-2025: 0.2%● unchanged vs 04-2025
06-2025: 0.2%● unchanged vs 05-2025
07-2025: 0.2%● unchanged vs 06-2025
08-2025: 0.3%▲ +0.1 percentage points vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025
10-2025: 0.3%● unchanged vs 09-2025
11-2025: 0.3%● unchanged vs 10-2025
12-2025: 0.2%▼ -0.1 percentage points vs 11-2025
01-2026: 0.2%● unchanged vs 12-2025
02-2026: 0.2%● unchanged vs 01-2026
03-2026: 0.3%▲ +0.1 percentage points vs 02-2026
04-2026: 0.3%● unchanged vs 03-2026
05-2026: 0.3%● unchanged vs 04-2026
06-2026: 0.2%▼ -0.1 percentage points vs 05-2026
07-2026: 0.3%▲ +0.1 percentage points vs 06-2026
08-2026: 0.4%▲ +0.1 percentage points vs 07-2026highest value
09-2026: 0.3%▼ -0.1 percentage points vs 08-2026
10-2026: 0.3%● unchanged vs 09-2026
11-2026: 0.3%● unchanged vs 10-2026
No credit on open account
The balance sheet total is too small for a liquidity verdict. Equity is negative.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 1% of them on solvency, 20% on liquidity, 1% on profitability and 25% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025Equity per financial year
1819202122232425
2018 to 2025 · latest year -€42,497
raises risk · 2025 accounts filed 28 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 28-08-2026, 28 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
28 days late
2024
111 days late
2023
61 days late
2022
150 days late
2021
61 days late
2020
87 days late
2019
122 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 89 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 October (4 of the last 5 accounts filed within 49 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
04-11-2026 today31-12-2026 year end31-07-2027 deadline
Financials
Financials · financial year 2025, full format
2025 annual accounts filed 28 days after the deadline Filed on 28 August 2026, deadline 31 July 2026 (7 months after the close on 31 December 2025, Companies Code art. 3:10). Source: NBB, 2026-00440274.
Annual accounts 2025 filed on 28-08-2026 at the NBB all 16 filings
Turnover
Not included in this filing
EBIT margin
Not included in this filing
Net result
-€4,762
2024 · €2,618
Working capital
-€5,252▼ 972%
2024 · -€490
Multi-year overview
2018 to 2025, 8 financial yearsOperating result
-€4,663
2025
20182025
Net result
-€4,762
2025
lowest quarter of the sector
20182025
Equity
-€42,497
▼ 12.6%
2025
lowest quarter of the sector
20182025
Total assets
€2,737
▼ 34.6%
2025
lowest quarter of the sector
20182025
Debt
€45,233
▲ 7.9%
2025
20182025
Working capital
-€5,252
▼ 972%
2025
lowest quarter of the sector
20182025
Solvency
no figure
2025
20182025
Current ratio
no figure
2025
20182025
Return on assets (ROA)
no figure
2025
20182025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line20182019202020212022202320242025
Operating result-€19,437--€11,236▲ 42.2%€1,492-€233-€2,976▼ 1,177%€2,040€2,713▲ 33.0%-€4,663
Net result-€19,605--€11,876▲ 39.4%€1,292below the sector's middle half-€311below the sector's middle half-€3,083below the sector's middle half▼ 892%€1,940below the sector's middle half€2,618below the sector's middle half▲ 34.9%-€4,762below the sector's middle half
Equity-€28,315--€40,191▼ 41.9%-€38,899below the sector's middle half▲ 3.2%-€39,210below the sector's middle half▼ 0.8%-€42,293below the sector's middle half▼ 7.9%-€40,353below the sector's middle half▲ 4.6%-€37,735below the sector's middle half▲ 6.5%-€42,497below the sector's middle half▼ 12.6%
Total assets€8,461-€795▼ 90.6%€1,095below the sector's middle half▲ 37.7%€3,098below the sector's middle half▲ 183%€2,602below the sector's middle half▼ 16.0%€693below the sector's middle half▼ 73.4%€4,184below the sector's middle half▲ 504%€2,737below the sector's middle half▼ 34.6%
Debt€36,776-€40,986▲ 11.4%€39,993▼ 2.4%€42,308▲ 5.8%€44,895▲ 6.1%€41,046▼ 8.6%€41,919▲ 2.1%€45,233▲ 7.9%
Working capital€4,921--€4,322below the sector's middle half-€617below the sector's middle half▲ 85.7%-€3,000below the sector's middle half▼ 386%-€4,735below the sector's middle half▼ 57.8%-€490below the sector's middle half▲ 89.7%-€5,252below the sector's middle half▼ 972%
Solvency-334.7%-
Current ratio3.77-
Return on assets (ROA)-231.7%-
above
within
below
The sector band is the middle half of the companies in Human health activities (NACE 86). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is a loss of €4,663, after a profit of €2,713 in 2024. It is the lowest result since 2021.
Key figures and ratios
Debt ≤ 1 year
€7,988▲
2024 · €4,674
Debt > 1 year
€37,245=
2024 · €37,245
The ratios are withheld because a balance sheet total of €2,737 is too small for a meaningful ratio.
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Investments
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Tangible fixed assets | €1,740 | - | - | - | - |
| Depreciation and write-downs of the year | €756 | €700 | €580 | €127 | - |
Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €15,967 | €1,680 | €372 | €756 | €700 | €580 | €127 | - | - |
| Other operating charges640/8 | - | - | - | €120 | €120 | €120 | €208 | €120 | ▼ 42.4% |
| Gross operating margin9900 | -€2,948 | -€9,027 | €2,020 | €643 | -€2,156 | €2,740 | €3,049 | -€4,543 | - |
| Operating profit (loss)9901 | -€19,437 | -€11,236 | €1,492 | -€233 | -€2,976 | €2,040 | €2,713 | -€4,663 | - |
| Recurring financial income75 | €0 | - | - | - | - | - | - | - | - |
| Financial charges65/66B | - | - | - | €78 | €107 | €100 | €96 | €98 | ▲ 2.7% |
| Recurring financial charges65 | €168 | €192 | €128 | €78 | €107 | €100 | €96 | €98 | ▲ 2.7% |
| Profit (loss) for the period before taxes9903 | -€19,605 | -€11,429 | €1,364 | -€311 | -€3,083 | €1,940 | €2,618 | -€4,762 | - |
| Income taxes67/77 | - | €447 | €72 | - | - | - | - | - | - |
| Profit (loss) for the period9904 | -€19,605 | -€11,876 | €1,292 | -€311 | -€3,083 | €1,940 | €2,618 | -€4,762 | - |
| Profit (loss) for the period to be appropriated9905 | -€19,605 | -€11,876 | €1,292 | -€311 | -€3,083 | €1,940 | €2,618 | -€4,762 | - |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||
| Total assets20/58 | €8,461 | €795 | €1,095 | €3,098 | €2,602 | €693 | €4,184 | €2,737 | ▼ 34.6% |
| Fixed assets21/28 | €1,764 | €795 | €423 | €1,407 | €707 | €127 | - | - | - |
| Tangible fixed assets22/27 | €1,725 | €795 | €423 | €1,407 | €707 | €127 | - | - | - |
| Furniture and vehicles24 | - | - | - | €1,407 | €707 | €127 | - | - | - |
| Financial fixed assets28 | €39 | - | - | - | - | - | - | - | - |
| Current assets29/58 | €6,696 | - | €671 | €1,691 | €1,895 | €566 | €4,184 | €2,737 | ▼ 34.6% |
| Cash at bank and in hand54/58 | €3,696 | - | €671 | €539 | €375 | €566 | €4,184 | €2,737 | ▼ 34.6% |
| Deferred charges and accrued income490/1 | - | - | - | €1,153 | €1,520 | - | - | - | - |
| Equity and liabilities | |||||||||
| Total equity and liabilities10/49 | €8,461 | €795 | €1,095 | €3,098 | €2,602 | €693 | €4,184 | €2,737 | ▼ 34.6% |
| Equity10/15 | -€28,315 | -€40,191 | -€38,899 | -€39,210 | -€42,293 | -€40,353 | -€37,735 | -€42,497 | ▼ 12.6% |
| Contributions10/11 | €19,600 | €19,600 | €19,600 | €19,600 | €19,600 | €19,600 | €19,600 | €19,600 | = |
| Capital10 | - | - | - | €19,600 | €19,600 | €19,600 | €19,600 | - | - |
| Issued capital100 | - | - | - | €19,600 | €19,600 | €19,600 | €19,600 | - | - |
| Contributions outside capital11 | - | - | - | - | - | - | - | €19,600 | - |
| Share premium1100/10 | - | - | - | - | - | - | - | €19,600 | - |
| Reserves13 | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | = |
| Non-distributable reserves130/1 | - | - | - | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | = |
| Legal reserve130 | - | - | - | €1,960 | €1,960 | €1,960 | €1,960 | €1,960 | = |
| Profit (loss) carried forward14 | -€49,875 | -€61,751 | -€60,459 | -€60,770 | -€63,853 | -€61,913 | -€59,295 | -€64,057 | ▼ 8.0% |
| Amounts payable17/49 | €36,776 | €40,986 | €39,993 | €42,308 | €44,895 | €41,046 | €41,919 | €45,233 | ▲ 7.9% |
| Amounts payable after more than one year17 | €35,000 | €35,000 | €35,000 | €40,000 | €40,000 | €35,745 | €37,245 | €37,245 | = |
| Other amounts payable178/9 | - | - | - | €40,000 | €40,000 | €35,745 | €37,245 | €37,245 | = |
| Amounts payable within one year42/48 | €1,776 | €5,986 | €4,993 | €2,308 | €4,895 | €5,301 | €4,674 | €7,988 | ▲ 70.9% |
| Trade debts44 | €21 | €607 | €210 | €299 | €348 | €862 | - | - | - |
| Suppliers440/4 | - | - | - | €299 | €348 | €862 | - | - | - |
| Other amounts payable47/48 | - | - | - | €2,009 | €4,547 | €4,439 | €4,674 | €7,988 | ▲ 70.9% |
| Line | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | -€19,605 | -€11,876 | €1,292 | -€311 | -€3,083 | €1,940 | €2,618 | -€4,762 | - |
| + Depreciation and write-downs630 | €15,967 | €1,680 | €372 | €756 | €700 | €580 | €127 | - | - |
| Operating cash flow (approximation) | -€3,638 | -€10,196 | €1,664 | €445 | -€2,383 | €2,520 | €2,745 | -€4,762 | - |
| Investment in fixed assets (approximation) | - | -€711 | €0 | -€1,740 | €0 | €0 | - | - | - |
| Change in cash | - | - | - | -€133 | -€164 | €191 | €3,618 | -€1,447 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 6,907 companies had the same profile as Dr. DEVOS MD has now. Two years later, 85.4% were still going and 5.8% had gone bankrupt.
- Micro
- 10 to 20 years old
- negative equity
- a loss of 10% of the balance sheet or more
85.4%
was still going
8.1%
stopped otherwise
5.8%
went bankrupt
Another 0.6% stopped without a precise date, possibly only after those two years.
The bankruptcy probability of Dr. DEVOS MD itself is lower: 0.3% within 12 months. It rests on far more data about Dr. DEVOS MD than the profile alone.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,907 companies, not a prediction for Dr. DEVOS MD. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Latest 10 of 16 filings with the National Bank
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 31-12-2025 | full format | 28-08-2026 | 2026-00440274 | |
| 31-12-2024 | full format | 19-11-2025 | 2025-00568713 | |
| 31-12-2023 | micro format | 30-09-2024 | 2024-00479696 | |
| 31-12-2022 | full format | 28-12-2023 | 2024-00540662 | |
| 31-12-2021 | full format | 30-09-2022 | 2022-20449992 | |
| 31-12-2020 | full format | 26-10-2021 | 2021-75000365 | |
| 31-12-2019 | full format | 30-11-2020 | 2020-74600470 | |
| 31-12-2018 | full format | 16-07-2019 | 2019-34100061 | |
| 31-12-2017 | full format | 24-09-2018 | 2018-64600098 | |
| 31-12-2016 | full format | 27-11-2017 | 2017-70600151 |
Board & ownership
Directors
Directors
1 director, last change in 2025
DEVOS Marie-Dominique
Current
Director (not named in the articles) · appointed in the act of 02-07-2025 · earlier manager, until 02-07-2025 · term without a fixed end · listed in the 2025 annual accounts, filed on 28-08-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
“Article 14 - Représentation externe Chaque administrateur représente la société à l’égard des tiers et en justice, soit en demandant, soit…”
deed of 02-07-2025Owners and capital
Capital transactions
Capital over time
- 02-07-2025 Converted to unavailable equity
Mandate history
1 person, 1 in office
- Board
- began earlier
| Name | Functions and periods |
|---|---|
| DEVOS Marie-Dominique |
|
Network & group
Dr. DEVOS MD shares no director with another company.
Companies at the same address
1 other companyConnections & network
1 current directorThe network starts from the directors of Dr. DEVOS MD. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
28-08
full format · 28 days late
2025
19-11
full format · 111 days late
02-07
Gazette deed
Change of role: DEVOS Marie-Dominique, from manager to directorCapital conversion · Purpose change · Amendment of the articles13 points ▸
Gazette deed
Change of role: DEVOS Marie-Dominique, from manager to director
Capital conversion · Purpose change · Amendment of the articles13 points ▸
- General meeting, 02-06-2025
- Other provision, “unanimité, adaptation statuts CSA conservation forme SRL” (deed in French)
- Capital conversion, “compte de capitaux propres statutairement indisponible” (deed in French)
- Other provision, “dispense lecture rapport organe administration modification objet, exemplaire rapport déposé au greffe Tribunal Entreprise compétent avec expédition procès-verb…” (deed in French)
- Purpose change
- Amendment of the articles
- Capital
- Power of attorney, Donatienne d'HARVENG
- Registered office clause, “7880 Flobecq, rue Sainte-Anne”, 9, “unanimité” (deed in French)
- Director resignation, DEVOS Marie-Dominique (manager)
- Director appointment, DEVOS Marie-Dominique (director (not named in the articles))
- Director discharge, DEVOS Marie-Dominique (gérant démissionnaire)
- The act holds 1 more point.
2024
31-12
Financial
Highest result from 2018 to 2025net €2,618 ▲34.9%
The operating result of €2,713 and the net result of €2,618 are both a record.
30-09
micro format · 61 days late
2023
31-12
Financial
Back to profitnet €1,940
The net result is €1,940, after 2 loss-making years.
28-12
full format · 150 days late
2022
30-09
full format · 61 days late
2021
26-10
full format · 87 days late
2020
31-12
Financial
Back to profitnet €1,292
The net result is €1,292, after 2 loss-making years.
30-11
full format · 122 days late
2019
16-07
full format · 15 days before the deadline
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
Dr. DEVOS MD in French
Enterprise number
0817.960.418
Legal form
Private limited company
Status
Active, normale toestand
Founded
21-08-2009
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 02-07-2025 (in French)Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Organe d’administration, Région Wallonne”
deed of 02-07-2025 (in French)Registered office and establishments
Registered office
Sainte-Anne 9, 7880 Flobecq, Belgium
Establishment units
Dr.DEVOS MD, Sterrenkundelaan 1, 1210 Sint-Joost-ten-Node since 09-09-2009 · unit number 2.180.787.553
Dr.DEVOS MD, Sainte-Anne 9, 7880 Flobecq since 09-09-2009 · unit number 2.180.787.751
Activities
NACEBEL 202586220
Specialist medical practice main activity
Codes under NACEBEL 2008
86220
Human health activities main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
deed of 02-07-2025 (in French)
“Médecine généraliste; Agréée en médecine du travail; Agréée médecin expert et médecin conseil des assurances; Spécialiste en médecine de…”
17 activities
- Médecine généraliste
- Agréée en médecine du travail
- Agréée médecin expert et médecin conseil des assurances
- Spécialiste en médecine de travaux subaquatiques et médecine hyperbare;spécialiste en oxygénothérapie hyperbare
- Spécialiste en brûlologie,plaies et cicatrisations
- Psychothérapeute:psychanalyste;ou par un ou plusieurs praticiens légalement habilités à exercer profession médecin en Belgique ainsi que toutes missions enseignement et recherche qui relèvent obligations professeur université en Belgique comme à Etranger
- But permettre pratiquer médecine qualité,respect déontologie,liberté thérapeutique et diagnostique,dignité,indépendance professionnelle praticien,libre choix patient,par amélioration et rationalisation équipement professionnel
- En assurant gestion centre médical ou cabinet médical,y compris acquisition,location,entretien matériel médical et biens équipement,facturation,perception honoraires médicaux,mise à disposition tout nécessaire à pratique art guérir,en permettant création,construction,location,acquisition,organisation et fonctionnement cabinet médical ou centre médical facilitant exercice médecine;en assurant défense intérêts professionnels,moraux,matériels praticiens travaillant dans cadre société
- Favoriser recherche scientifique en organisant activités recyclage et nouant avec tous organismes poursuivant mêmes buts relations nécessaires à réalisation objet
- En organisant séminaires à but thérapeutique en relation avec activités médicales précitées,en Belgique ou à étranger
- Consultant en travaux hyperbares
- En assurant par tous moyens nécessaires,notamment par participation à séminaires promotion nationale et internationale activité médicale et pédagogique associés actifs
- Peut exercer toute activité susceptible favoriser réalisation objet social et,moyennant accord Conseil provincial compétent Ordre Médecins,s'intéresser par toutes voies dans toutes entreprises ayant but identique,analogue ou connexe ou de nature à favoriser développement propre activité
- Peut accomplir toutes opérations financières,mobilières ou immobilières se rapportant directement ou indirectement à objet social mais n'altérant pas caractère civil société et vocation médicale et pédagogique
- Associés conviennent apporter ou mettre en commun totalité activité médicale,honoraires générés perçus au nom et pour compte société
- Interdit toute forme commercialisation médecine,collusion directe et indirecte,dichotomie,surconsommation
- À titre accessoire,constitution au départ bénéfices réservés,gestion,valorisation patrimoine mobilier et immobilier,notamment par achat,vente,location,mise en location,construction,au sens plus large,pour autant que altérés ni caractère civil ni vocation prioritairement médicale,et que opérations dans limites gestion en bon père de famille sans caractère répétitif et commercial
Invoicing and payment
VAT number
BE 0817.960.418
Financial year and general meeting
Accounts at the NBBFinancial year end
31-12
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
15 June at 18:00
deed of 02-07-2025 (in French)Sites & property
Location
Buildings and parcels at the addresses
Ground area
4,521 m²
Building footprint
1,647 m²
Building volume
55,815 m³
Tallest building: 49.5 m.
Wallonia
1
(50%)
Brussels
1
(50%)
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 51019C0500/00H000 | Wallonia | 2,334 m² | 1 · 183 m² | 7.0 m · 2 |
| 21572B0524/00D000 | Brussels | 2,186 m² | 1 · 1,464 m² | 49.5 m · 14 |
1 of these parcels carries protected heritage. Expect extra rules on renovation or sale.